![Higher naloxone doses have no impact on overdose survival, study shows](https://www.harmreductiontherapeutics.org/wp-content/uploads/2024/07/stat_logo_trans.png)
![Higher naloxone doses have no impact on overdose survival, study shows](https://www.harmreductiontherapeutics.org/wp-content/uploads/2024/07/stat_logo_trans.png)
![Comparison of Administration of 8-Milligram and 4-Milligram Intranasal Naloxone by Law Enforcement During Response to Suspected Opioid Overdose](https://www.harmreductiontherapeutics.org/wp-content/uploads/2024/07/cdc_logo_trans.png)
Comparison of Administration of 8-Milligram and 4-Milligram Intranasal Naloxone by Law Enforcement During Response to Suspected Opioid Overdose
In 2021, an 8-mg intranasal naloxone product was approved by the Food and Drug Administration; however, no studies have examined outcomes among persons who receive the 8-mg naloxone product and those who receive the usual 4-mg product…![US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals](https://www.harmreductiontherapeutics.org/wp-content/uploads/2022/11/pink-sheet-2-1.png)
US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals
![OTC Naloxone One Step Closer as Harm Reduction Therapeutics Initiates a Rolling Submission of its New Drug Application to U.S. FDA for RiVive™ for Emergency Treatment of Opioid Overdose](https://www.harmreductiontherapeutics.org/wp-content/uploads/2022/12/HarmReductionTherapeuticsLogoA21_post.png)
OTC Naloxone One Step Closer as Harm Reduction Therapeutics Initiates a Rolling Submission of its New Drug Application to U.S. FDA for RiVive™ for Emergency Treatment of Opioid Overdose
![OTC Naloxone One Step Closer as Harm Reduction Therapeutics Initiates a Rolling Submission of its New Drug Application to U.S. FDA for RiVive™ for Emergency Treatment of Opioid Overdose](https://www.harmreductiontherapeutics.org/wp-content/uploads/2022/12/HarmReductionTherapeuticsLogoA21_post.png)